Table 6 Conditional logistic regression model on the endpoint infection (yes/no) including all patients receiving three consolidation cycles

From: Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

 

OR

CI

P-value

HDAC-123a

0.58

0.45–0.74

<0.0001

Pegfilgrastim

0.68

0.54–0.87

0.002

Age (10 years difference)

1.07

0.96–1.19

0.22

ELN risk group b ,2

 Low

1.06

0.80–1.39

0.70

 Intermediate 2

0.99

0.67–1.45

0.94

 High

1.10

0.62–1.92

0.75

Male gender

1.04

0.83–1.31

0.71

s/t-AML

1.62

1.01–2.60

0.05

  1. Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; HDAC, high-dose cytarabine; ELN, European LeukemiaNet; OR, odds ratio; s/t-AML, secondary AML after a proceeding myelodysplastic syndrome/treatment related AML.
  2. aReference group, HDAC-135.
  3. bReference group, intermediate 1.
Back to article page